Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Treatment-naive adult patients with advanced (unresectable or metastatic) BRAF V600 WT melanoma
Hint of lesser benefit of nivolumab + ipilimumab versus nivolumab
Additional information
Federal Joint Committee (G-BA)
2017-12-07 A G-BA decision was published.
Project details
- Project no.
- A17-27
- Commission
- Commission awarded on 15.06.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (NSCLC, perioperative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (unresectable or metastatic urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed